Elevance Health, Inc. (NYSE:ELV) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC decreased its stake in Elevance Health, Inc. (NYSE:ELV - Free Report) by 8.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 41,788 shares of the company's stock after selling 4,033 shares during the quarter. Yousif Capital Management LLC's holdings in Elevance Health were worth $19,706,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ELV. Sanders Capital LLC boosted its position in Elevance Health by 1.4% in the 3rd quarter. Sanders Capital LLC now owns 4,261,976 shares of the company's stock worth $1,855,750,000 after purchasing an additional 58,013 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in Elevance Health by 0.9% during the fourth quarter. Baillie Gifford & Co. now owns 3,087,904 shares of the company's stock worth $1,456,132,000 after buying an additional 27,986 shares in the last quarter. Morgan Stanley grew its position in Elevance Health by 1.7% during the third quarter. Morgan Stanley now owns 2,784,714 shares of the company's stock valued at $1,212,521,000 after buying an additional 46,322 shares during the period. Northern Trust Corp increased its holdings in Elevance Health by 2.4% in the third quarter. Northern Trust Corp now owns 2,416,459 shares of the company's stock valued at $1,052,175,000 after buying an additional 57,098 shares in the last quarter. Finally, Artisan Partners Limited Partnership raised its position in shares of Elevance Health by 7.2% in the third quarter. Artisan Partners Limited Partnership now owns 2,379,046 shares of the company's stock worth $1,035,884,000 after acquiring an additional 160,524 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of Elevance Health stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total value of $376,500.00. Following the sale, the director now owns 9,109 shares in the company, valued at $4,554,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Truist Financial restated a "buy" rating and issued a $600.00 price target (up previously from $580.00) on shares of Elevance Health in a research note on Friday. StockNews.com downgraded Elevance Health from a "strong-buy" rating to a "buy" rating in a research note on Thursday, January 25th. Barclays lifted their price target on shares of Elevance Health from $584.00 to $621.00 and gave the company an "overweight" rating in a research note on Friday. Wells Fargo & Company increased their price objective on shares of Elevance Health from $557.00 to $600.00 and gave the company an "overweight" rating in a report on Friday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $580.00 target price on shares of Elevance Health in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $587.64.

Elevance Health Price Performance

ELV traded up $0.70 during trading on Tuesday, reaching $532.92. The company's stock had a trading volume of 796,340 shares, compared to its average volume of 1,066,078. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.54. The firm has a fifty day simple moving average of $510.23 and a two-hundred day simple moving average of $485.10. The company has a market cap of $123.86 billion, a price-to-earnings ratio of 20.14, a PEG ratio of 1.16 and a beta of 0.78. Elevance Health, Inc. has a 1 year low of $412.00 and a 1 year high of $539.11.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings data on Thursday, April 18th. The company reported $10.64 EPS for the quarter, topping analysts' consensus estimates of $10.54 by $0.10. The firm had revenue of $42.27 billion for the quarter, compared to the consensus estimate of $42.49 billion. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The firm's revenue was up .9% compared to the same quarter last year. During the same quarter last year, the business posted $9.46 earnings per share. As a group, analysts anticipate that Elevance Health, Inc. will post 37.24 EPS for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Stockholders of record on Monday, June 10th will be paid a $1.63 dividend. The ex-dividend date is Monday, June 10th. This represents a $6.52 annualized dividend and a dividend yield of 1.22%. Elevance Health's dividend payout ratio (DPR) is 24.64%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.